Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018200146) SYNERGISTIC COMBINATION OF NUCLEIC ACID OLIGONUCLEOTIDES AND APOPTOSIS-INDUCING MOLECULAR THERAPEUTICS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/200146 International Application No.: PCT/US2018/026181
Publication Date: 01.11.2018 International Filing Date: 05.04.2018
IPC:
C07H 21/04 (2006.01) ,C12N 15/11 (2006.01) ,C12N 15/113 (2010.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04
with deoxyribosyl as saccharide radical
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants:
JIVANA BIOTECHNOLOGY INC. [US/US]; 108 West 13th Street Wilmington, DE 19801, US
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS [US/US]; 352 Henry Administration Building 506 South Wright Street Urbana, IL 61801, US
Inventors:
HOPPS, Sidney; US
MATHUR, Aditi; US
PRABHAKAR, Bellur; US
YUE, Fei; US
SAINI, Shikha; US
Agent:
SAGE, G. Patrick; US
Priority Data:
62/489,09724.04.2017US
Title (EN) SYNERGISTIC COMBINATION OF NUCLEIC ACID OLIGONUCLEOTIDES AND APOPTOSIS-INDUCING MOLECULAR THERAPEUTICS
(FR) COMBINAISON SYNERGIQUE D'OLIGONUCLÉOTIDES D'ACIDE NUCLÉIQUE ET D'AGENTS THÉRAPEUTIQUES MOLÉCULAIRES INDUISANT L'APOPTOSE
Abstract:
(EN) The invention provides compositions and methods for treating cancers comprising administering a combination of antineoplastic agents, wherein the combination comprises apoptosis-inducing molecular therapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not ail splice variants of the IG20 gene are down-regulated. In an embodiment, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD spiice variant. The invention encompasses methods of treating cancers which include combination therapy with nucleic acid molecules capable of down-regulating the expression of the at ieast one splice variant of the IG20 gene, and apoptosis-inducing molecular therapeutics.
(FR) L'invention concerne des compositions et des méthodes de traitement de cancers comprenant l'administration d'une combinaison d'agents antinéoplasiques, où la combinaison comprend des agents thérapeutiques moléculaires induisant l'apoptose et une ou plusieurs molécules d'acide nucléique capables de réguler à la baisse l'expression d'au moins un variant d'épissage du gène IG20, et où tous les variants d'épissage du gène IG20 ne sont pas régulés à la baisse. Dans un mode de réalisation, le variant d'épissage du gène IG20 est un variant d'épissage MADD et les molécules d'acide nucléique sont des ARNsi, ARNsh et oligonucléotides antisens qui comprennent une séquence d'acide nucléique complémentaire d'une séquence d'acide nucléique de l'exon 13L du variant d'épissage MADD ou d'un transcrit ARNm de l'exon 13L du variant d'épissage MADD. L'invention concerne des méthodes de traitement de cancers qui comprennent une polythérapie à base de molécules d'acide nucléique capables de réguler à la baisse l'expression d'au moins un variant d'épissage du gène IG20, et d'agents thérapeutiques moléculaires induisant l'apoptose.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)